In Finland, nicotine pouches are subject to a specific taxation system that is tied to their strength. The tax is calculated based on the nicotine content per pouch, meaning that higher-strength pouches incur higher taxes. This system aims to discourage the use of high-nicotine products, promoting public health by making them less financially attractive. It’s…
The illicit nicotine pouch market is expanding rapidly, echoing the challenges faced during the early days of the unregulated e-vapor market. Without decisive action, this unregulated sector poses risks to public health, undermines harm reduction efforts, and creates an unfair playing field for compliant manufacturers. Understanding the root causes and addressing the issue with a…
A recent revelation from a leaked confidential document distributed by the European Commission’s consultant has sent ripples across the nicotine pouch industry. The document reportedly recommends a complete ban on nicotine pouches within the European Union, citing concerns over youth appeal, insufficient regulation, and perceived risks. This proposal has ignited significant debate among public health…
Norway is witnessing a profound shift in its approach to tobacco use, driven by consumer preferences and product innovation. The rise of snus, a smokeless, tobacco-containing product, has significantly reshaped the country’s public health landscape. This consumer-led movement demonstrates the transformative potential of harm reduction strategies and highlights the importance of providing safer alternatives for…
The rise of modern oral nicotine products, such as nicotine pouches and lozenges, represents a significant shift in the tobacco harm reduction landscape. These tobacco-free alternatives are increasingly being adopted by adult consumers seeking safer nicotine delivery options. However, with their rapid growth, global regulatory bodies face the challenge of establishing robust frameworks that balance…
We are thrilled to announce the appointment of Phil Hudson as the newest member of the GINN team. Phil will spearhead membership and outreach initiatives across the UK and European markets, bringing a wealth of experience and insight to our mission of advancing tobacco harm reduction and fostering innovation in the novel nicotine industry. A…
The U.S. Food and Drug Administration (FDA) has taken a landmark step in tobacco harm reduction by authorizing the marketing of 20 ZYN nicotine pouch products. This authorization, granted under the Premarket Tobacco Product Application (PMTA) process, establishes a clear regulatory pathway for nicotine pouches, reinforcing their role as a viable alternative for adult smokers…
The growing popularity of nicotine pouches as a smoke-free alternative has positioned them as a pivotal tool in tobacco harm reduction. However, their rapid market growth has also drawn increased regulatory scrutiny, particularly in the European Union (EU). As policymakers deliberate over the future of these products, the question arises: Could nicotine pouches face stricter…
The rise of nicotine pouch use in Great Britain, while modest, signals a pivotal shift in tobacco consumption trends. According to a new study published in Nicotine and Tobacco Research by Dr. Leonie Brose, Laura Bunce, and Hazel Cheeseman, nicotine pouch usage has reached 5.4%. However, only 1% of respondents reported current use, suggesting that…
1. Executive Summary Safer nicotine products (SNPs), such as nicotine pouches, lozenges, gums, dissolvables and other reduced-risk nicotine alternatives, should not be regulated in the same manner as combustible smoking tobacco products and nicotine vaping products because they– • are smokeless and do not pose the same relative health risks; • readily contribute to a…